BRADLEY PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS
(UNAUDITED)
Three Months Ended Nine Months Ended
September 30, September 30,
---------------------- ----------------------
2000 1999 2000 1999
---------------------- ----------------------
Netsales $ 4,667,772 $ 4,128,173 $11,556,819 $13,544,105
Cost of sales 1,060,740 1,070,773 2,915,107 3,725,770
---------- ---------- ---------- ----------
3,607,032 3,057,400 8,641,712 9,818,335
---------- ---------- ---------- ----------
Selling, general and
administrative expenses 2,695,508 2,880,761 8,103,652 7,851,404
Depreciation and amortization 225,521 257,305 707,598 896,355
Interest expense - net 70,229 51,014 182,167 173,088
Loss due to impairment of asset - - 3,897,000 -
---------- ---------- ---------- ----------
2,991,258 3,189,080 12,890,417 8,920,847
---------- ---------- ---------- ----------
Income (loss) before
income taxes 615,774 (131,680) (4,248,705) 897,488
Income tax expense (benefit) 240,000 (48,000) (137,000) 332,000
---------- ---------- ---------- ----------
Net income (loss) $ 375,774 $ (83,680) $(4,111,705)$ 565,488
========== ========== ========== ==========
Net income (loss)
per common share
Basic & Diluted $ 0.05 $ (0.01) $ (0.52)$ 0.07
========== ========== ========== ==========
Weighted average number
of common shares
Basic 7,910,000 7,900,000 7,900,000 8,010,000
========== ========== ========== ==========
Diluted 7,960,000 7,930,000 7,900,000 8,070,000
========== ========== ========== ==========
See Notes to Condensed Consolidated Financial Statements
4
